James Cullem, Allarity interim CEO

Af­ter FDA re­quests a new tri­al, Al­lar­i­ty drops a can­cer drug from so­lo de­vel­op­ment

The US-Dan­ish biotech Al­lar­i­ty Ther­a­peu­tics is hav­ing to piv­ot its pipeline strat­e­gy af­ter the FDA forced them to go back to the draw­ing board for an on­col­o­gy ther­a­py.

Al­lar­i­ty an­nounced on Tues­day that the board has man­dat­ed the biotech to re­fo­cus its on­col­o­gy strat­e­gy away from the de­vel­op­ment of monother­a­pies and to­ward the de­vel­op­ment of “more promis­ing and clin­i­cal­ly rel­e­vant com­bi­na­tion ther­a­pies.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.